ArticleClinical and experimental medicine2026
The mystery of BMI in Sjögren's disease: unravelling complex relationships between BMI and multiple laboratory parameters.
Article in Clinical and experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The relationship between body mass index (BMI) and laboratory parameters in Sjögren's disease (SjD) remains unclear. We evaluated associations of BMI with selected serological and haematological parameters and explored its relationship with the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI). This single-centre retrospective cross-sectional study included 554 unique hospitalised patients with SjD. Multivariable linear regression models were adjusted for age, sex and disease duration. Effect estimates were expressed per 5 kg/m² higher BMI, and Benjamini-Hochberg false discovery rate correction was applied across all estimable laboratory outcomes. Generalised additive and segmented regression models examined nonlinear relationships. Natural-log-transformed CRP and TNF-α analyses and an ESSDAI score excluding both biological and haematological domains were used as sensitivity analyses. After adjustment for age, sex and disease duration, each 5 kg/m² higher BMI was associated with lower IgG and higher C3, HGB, WBC and RBC after false discovery rate correction. CRP showed a nominal inverse association (P = 0.038, q = 0.076). TNF-α showed no linear association, but U-shaped patterns were observed in raw and log-transformed analyses. BMI was weakly inversely correlated with ESSDAI (ρ=-0.160, P < 0.001) and very weakly with ESSDAI excluding the biological and haematological domains (ρ=-0.085, P = 0.044). BMI was associated with several laboratory parameters and weakly with ESSDAI in this hypothesis-generating cross-sectional study. The underlying mechanisms remain uncertain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.